HEALTHCARE COSTS IN WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER TREATED WITH CDK4/6 INHIBITORS

被引：0
作者：
Burne, R. [1 ]
Balu, S. [2 ]
Guerin, A. [1 ]
Liang, Y. [1 ]
Schloessmann, R. [3 ]
Bungay, R. [1 ]
Paul, M. L. [2 ]
机构：
[1] Anal Grp Inc, Montreal, PQ, Canada
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Anal Grp Inc, Chicago, IL USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN120
引用
收藏
页码：S44 / S44
页数：1
相关论文
共 50 条
  • [41] Treatment patterns of patients with HR+/HER2-metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database
    Read, Stephanie H.
    Quignot, Nadia
    Kapso-Kapnang, Raissa
    Comerford, Erin
    Zheng, Ying
    Gainford, Corona
    Sasane, Medha
    Vataire, Anne-Lise
    Delzongle, Laure
    Bidard, Francois-Clement
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 204 (03) : 579 - 588
  • [42] Characterizing demographics, clinical, and genomic characteristics for US patients with HR+, HER2-metastatic breast cancer following progression on a CDK4 and 6 inhibitor.
    Andre, Fabrice
    Aggarwal, Amit
    Rao, Xi
    Chen, Yongmei
    Beyrer, Julie Kay
    Smyth, Emily Nash
    Guimaraes, Claudia Morato
    Litchfield, Lacey
    Bowman, Lee
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2-metastatic breast cancer in the United States: A SEER-Medicare population-based study
    Goyal, Ravi K.
    Chen, Hua
    Abughosh, Susan M.
    Holmes, Holly M.
    Candrilli, Sean D.
    Johnson, Michael L.
    CANCER, 2023, 129 (07) : 1051 - 1063
  • [44] Activation of the AKT/mTOR signaling pathway is associated with response to the combination of endocrine therapy and CDK4/6 inhibitor in HR+/HER2-metastatic breast cancer
    Abu-Khalaf, Maysa
    Hatzis, Christos
    Hodge, K. Alex
    Baldelli, Elisa
    Sikov, William
    Mita, Monica
    Valdes-Albini, Frances
    Dunetz, Bryant
    Petricoin, Emanuel
    Pierobon, Mariaelena
    CANCER RESEARCH, 2022, 82 (04)
  • [45] Cellular senescence in the response of HR+ breast cancer to radiotherapy and CDK4/6 inhibitors
    Klapp, Vanessa
    Buque, Aitziber
    Bloy, Norma
    Sato, Ai
    Yamazaki, Takahiro
    Zhou, Xi Kathy
    Formenti, Silvia C.
    Galluzzi, Lorenzo
    Petroni, Giulia
    JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
  • [46] Advances in the mechanism of CDK4/6 inhibitor resistance in HR+/HER2-breast cancer
    Wu, Sijia
    Xu, Junnan
    Ma, Yiwen
    Liang, Guilian
    Wang, Jiaxing
    Sun, Tao
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [47] Abemaciclib in HR+/HER2-metastatic breast cancer: A realworld experience
    Bottosso, M.
    Giarratano, T.
    Barbieri, C.
    Menichetti, A.
    Cumerlato, E.
    Miglietta, F.
    Genovesi, E.
    Amato, O.
    Dieci, M. V.
    Griguolo, G.
    Guarneri, V.
    ANNALS OF ONCOLOGY, 2021, 32 : S73 - S74
  • [48] The educational impact of a curriculum for oncologists on the latest developments in the use of CDK4/6 inhibitors in HR+/HER2-early and metastatic breast cancer
    Dorkhom, N.
    Ragoonath-Cameron, D.
    Bahra, S.
    Patel, U.
    Phoenix, V.
    ANNALS OF ONCOLOGY, 2022, 33 : S159 - S160
  • [49] Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2– metastatic breast cancer in the United States
    Ravi K. Goyal
    Holly M. Holmes
    Hua Chen
    Susan Abughosh
    Sean D. Candrilli
    Michael L. Johnson
    Breast Cancer Research and Treatment, 2023, 198 : 159 - 166
  • [50] Should CDK4/6 inhibitors replace chemotherapy in HR+ /HER2− metastatic breast cancer with visceral crisis? Evaluating the emerging evidence
    Armando Orlandi
    Discover Oncology, 16 (1)
12345